Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when
characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted …

Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …

Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements
generally have a progression-free survival of 8–11 months while on treatment with the ALK …

Purpose We performed a multi-institutional study to identify prognostic factors and determine
outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain …

Background Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is
increasingly being considered in the setting of oligoprogression to delay the need to change …

Purpose Patients with stage IV non–small-cell lung cancer (NSCLC) who progress through
first-line therapy have poor progression-free survival (PFS) and overall survival (OS), most …

Background and purpose Both stereotactic radiotherapy (SRT) and immune-or targeted
therapy play an increasingly important role in personalized treatment of metastatic disease …

Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in
a large population of unselected patients with ALK-positive non-small-cell lung cancer …

Anaplastic lymphoma kinase-rearranged lung cancer is associated with significant response
to crizotinib. However, resistance to crizotinib typically develops within 1-2 years. Preclinical …